What Nathaniel Taught Me About Second Chances

I have spent much of my career talking about Cell and Gene Therapy in the language of policy such as infrastructure investment, regulatory pathways, subsidy frameworks. It is necessary language, but it is also, I will admit, somewhat bloodless. Sitting across from Nathaniel a few weeks ago, listening to him walk me through brain fog, a shoulder that kept clipping door frames, and fourteen days of waiting for his own frozen stem cells to bring him back from zero, I was reminded why SSCTR exists in the first place. Policy is downstream of people. I want to use this space to reflect on three things his story made unmistakably clear to me.

What Cell and Gene Therapy really means when conventional treatment runs out

For most of the twentieth century, oncology offered patients a fairly blunt toolkit: cut it out, burn it, or poison it faster than it could poison you. Nathaniel lived that reality in full - four brutal cycles of MATRix chemotherapy that took his hair, his taste, and his neutrophil count to absolute zero, again and again. That regimen bought him remission. It did not buy him security. His oncologist was honest with him: without an Autologous Stem Cell Transplant, the lymphoma was likely to return, and a relapse of Primary CNS Lymphoma is a very different, far grimmer conversation.

This is what Cell and Gene Therapy actually means to a patient in that position. It is not an upgrade or a luxury add-on to standard care. For someone who has already been pushed to the edge of what conventional treatment can offer, ASCT, and further along the same continuum, therapies like CAR T-cell, is often the only remaining bridge between remission and cure, or between relapse and no options at all. Nathaniel described his transplant as "the hardest mountain I've ever had to climb," and I believe him. But he climbed it because the alternative was not a lesser mountain, it was no path forward at all. That distinction is easy to lose in a boardroom discussion about cost-effectiveness. It is impossible to lose once you have heard it from the person who lived it.

The barriers that still stand in the way

The part of our conversation that stayed with me longest, however, was not about Nathaniel's own treatment. It was about what he learned while receiving it in Australia, one of the most developed healthcare systems in the world.

Even there, next-generation cellular therapies like CAR T-cell therapy sit behind a wall of restriction. The cost is extraordinary. Often exceeding a million ringgit per patient, so public subsidy is typically reserved only for those who have already failed multiple lines of standard chemotherapy or relapsed. Private insurance, in most cases, does not cover it at all. If a patient falls outside the narrow subsidy criteria, the therapy becomes something only the wealthiest families can afford out of pocket. Nathaniel put it plainly: a treatment that could save your life becomes, for most people, simply theoretical.

This tells us that the barrier to Cell and Gene Therapy is rarely the science anymore. The science works. The barrier is access. Access shaped by cost, by eligibility criteria written around scarcity rather than need, by the absence of local infrastructure, and, for Sarawakians specifically, by the simple fact that receiving this care today means leaving home. Nathaniel had the means, the timing, and a diagnosis urgent enough to get him on a plane to Brisbane. Not every Sarawakian facing the same diagnosis will have all three.

What this means for Sarawak

This is where Nathaniel's story stops being one man's medical history and becomes, in my view, a direct message to those of us shaping the future Sarawak Cancer Centre. We have an opportunity, and I would argue an obligation, to build something that does not simply replicate the treatment landscape of the past, but closes the exact gap Nathaniel had to cross by leaving the country.

Concretely, that means a few things. It means investing early in the foundational capability such as local stem cell harvesting, processing, and transplant infrastructure, so that ASCT, the therapy that gave Nathaniel his cure, does not require a flight to Brisbane, Singapore, or beyond. It means training and retaining the specialised clinical and laboratory workforce that this kind of medicine depends on, since equipment without expertise is just very expensive furniture. It means working with our state government from the outset on subsidy and financing frameworks, so that eligibility for advanced therapies like CAR T-cell is designed around clinical need rather than what a family can privately afford. And it means building partnerships with established international CGT centres, so that Sarawak is not starting this work from zero, but building on proven protocols and reducing the years it would otherwise take to reach international standards of care.

None of this happens quickly, and I do not want to pretend otherwise. But every one of these steps is a choice, not an inevitability. The Sarawak Cancer Centre can be built to the standard of the past, or it can be built to close the distance between a Sarawakian patient and the therapy that might save their life. Nathaniel's second chance came from a transplant unit thousands of kilometres from home. My hope, and the reason SSCTR does this work, is that the next Sarawakian who needs that same second chance will not have to leave Sarawak to find it.

To Nathaniel: thank you for trusting us with your story. It has already done more to clarify our mission than any policy brief I have written.

Dr. Samuel Ting

President

Sarawak Society for Cell and Gene Therapy Research